Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06458803
Other study ID # TJ-IRB202404119
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 6, 2013
Est. completion date November 19, 2023

Study information

Verified date June 2024
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Immune thrombocytopenia (ITP) is a haemorrhagic disorder often associated with CTD. Corticosteroids are the first-line treatment for CTD-associated thrombocytopenia, but not all patients respond well. Eltrombopag is an oral, small molecule thrombopoietin receptor agonist. It interacts with the transmembrane domain of the thrombopoietin receptor and stimulates platelet production. This study is designed to evaluate the efficacy and safety of eltrombopag in patients with refractory CTD-ITP. It is a single-centre, retrospective, observational study involving a cohort of 52 patients diagnosed with CTD-RITP who received eltrombopag between 2013 and 2023. Follow-up data will be systematically collected and analysed to evaluate the therapeutic efficacy and safety of the drug. The study will provide valuable insight into the benefit of eltrombopag in CTD-RITP by reviewing baseline characteristics and performing subsequent clinical assessments to determine drug response and adverse events.


Description:

Immune thrombocytopenia (ITP) is a hemorrhagic disorder typically attributed to the formation of autoantibodies against platelet antigens. Patients experience decreased platelet count, clinically presenting as purpura, petechiae, mucosal bleeding, and increased menstrual bleeding. ITP is often associated with connective tissue diseases (CTD), with reports indicating a concurrent presence of ITP in 10%-15% of systemic lupus erythematosus (SLE) patients and 7.8% of primary Sjögren's syndrome (SS) patients. Currently, corticosteroids are the first-line therapy for CTD-associated thrombocytopenia, with second-line options including immunosuppressive agents, intravenous immunoglobulin (IVIG), splenectomy, and rituximab. However, not all patients respond favorably to these treatments. Patients with CTD who are unresponsive or have a low response to conventional first- and second-line therapies, with platelet counts below 30×10^9/L, are considered to have CTD-related refractory ITP (RITP). There are currently no internationally unified diagnostic criteria for RITP. For adult RITP diagnosis, criteria proposed by George et al. include: being diagnosed with ITP under the premise that treatment with glucocorticoids and/or splenectomy is ineffective; age ≥18 years; ③ duration of illness >6 months; ④ absence of other conditions causing thrombocytopenia; ⑤ platelet count ≤30×10^9/L. Eltrombopag is an oral, small-molecule, non-peptide thrombopoietin receptor agonist that interacts with the transmembrane domain of the thrombopoietin receptor, stimulating platelet production and increasing platelet counts. To evaluate the efficacy and safety of eltrombopag in CTD-RITP, this study will conduct a single-center retrospective observational analysis of 52 patients with CTD-RITP who received eltrombopag treatment between 2013 and 2023, recording their follow-up information. Patient characteristics at baseline will be analyzed, and drug efficacy and safety will be assessed through follow-up examinations at different time points. During treatment, patients may receive other ITP medications for maintenance therapy (such as glucocorticoids, azathioprine, danazol, cyclosporine A, and mycophenolate mofetil), excluding those concurrently using other TPO receptor agonists. Patient follow-up examinations will be continuously recorded (for at least six months, with monthly records, and patients followed until the last follow-up time if less than six months). Univariate analysis (descriptive analysis or non-parametric tests), single and multiple logistic regression analysis, and multiple correspondence analysis (MCA) will be used to analyze early clinical predictive factors for drug response. Patient drug responsiveness will be judged based on laboratory test results and clinical symptoms: ① Complete remission (CR): PLT ≥100×10^9/L with no bleeding tendency; ② Partial remission (PR): PLT ≥50×10^9/L but <100×10^9/L with no bleeding tendency, or platelet count at least twice that of pre-treatment; ③ No remission (NR): Does not meet criteria ① or ②. Mann-Kendall test will be used to analyze trends in PLT changes among patients during treatment, and the rates of CR, PR, and NR at different time points (4, 8, 12, 24 weeks) will be calculated to determine drug onset time and remission degree. The incidence of major adverse reactions to eltrombopag (hepatotoxicity, thrombosis) will be statistically analyzed at 24 weeks to assess drug safety. This project aims to evaluate the efficacy and safety of eltrombopag in treating CTD-RITP patients, providing evidence for formulating treatment plans for CTD-RITP patients. It aims to guide physicians in considering the use of eltrombopag when selecting treatment methods, understanding individual differences in patient response to eltrombopag efficacy, and helping physicians develop more personalized treatment plans based on early clinical predictive factors to improve treatment targeting and effectiveness. Furthermore, it aims to observe the long-term effects of eltrombopag treatment and explore the optimal dosage, course of treatment, and best combination therapy with other drugs.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date November 19, 2023
Est. primary completion date May 11, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. The patient is diagnosed with CTD, SLE, SS, APS, MCTD, ANCA or RA according to international diagnostic criteria; 2. The patient meets the diagnostic criteria of RITP: (i) glucocorticoid therapy and/or splenectomy is ineffective; (ii) age =18 years; (iii) duration of the disease >6 months; (iv) no other diseases leading to thrombocytopenia; (v) platelet count =30×109/L; 3. At the time of enrolment, patients have received ineffective conventional first-line treatment for one year or more; 4. Enrolled patients need to be aware of the clinical information they are being given. Exclusion Criteria: 1. The patient has a history of lymphoproliferative disease or malignancy of any organ system within the last 5 years; 2. The patient has a combination of other autoimmune diseases or malignant haematological diseases; 3. Patient's intermittent use of medication and failure to take medication as prescribed; 4. Patient refuses to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Eltrombopag
patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity,with the treatment of DMARDs at minimal or routine dosages.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary platelet counts of 52 patients from baseline after taking eltrombopag (Therapeutic effects-for refractory CTD-related ITP) Platelet counts are measured to determine remission status (CTD-RITP). Partial remission is defined as platelet counts = 50 × 10^9/L, and complete remission is defined as platelet counts = 100 × 10^9/L. Baseline, post-intervention week 4, post-intervention week 8, post-intervention week 12, post-intervention week 24
Secondary changes in disease activity index (Systemic Lupus Erythematosus Disease Activity Index 2000 for SLE patients and EULAR Sjögren's Syndrome Disease Activity Index 2000 for pSS patients) from baseline after taking Eltrombopag Disease activities are measured in SLE patients by the SLEDAI (systemic lupus erythematosus disease activity index 2000) and in SS patients by the ESSDAI (EULAR Sjögren's syndrome disease activity index 2000), which indicate patients' remission from treatment. For Systemic Lupus Erythematosus Disease Activity Index 2000, the minimum score is 0 and the maximum score is 105. With a score of 5 or more, the disease is considered active. For EULAR Sjögren's Syndrome Disease Activity Index 2000, the minimum score is 0 and the maximum score is 51. With a score of 5 or more, the disease is considered active. The lower the disease activity, the more effective Eltrombopag is. Baseline, post-intervention week 4, post-intervention week 8, post-intervention week 12, post-intervention week 24
See also
  Status Clinical Trial Phase
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Active, not recruiting NCT03688191 - Study of Sirolimus in CTD-TP in China Phase 4
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Recruiting NCT04918524 - The Clinical Features and Pregnancy Outcomes of CTD Patients
Recruiting NCT04993885 - Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2
Not yet recruiting NCT05998759 - Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia Phase 2
Recruiting NCT05065814 - Connective Tissue Diseases and Vitamin D Deficiency N/A
Completed NCT03494036 - Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease N/A
Completed NCT03929120 - Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD) Phase 1
Completed NCT00001330 - Study of Silicone-Associated Connective Tissue Diseases N/A
Not yet recruiting NCT05980728 - Connective Tissue Disease Patients With Pulmonary Hypertension
Not yet recruiting NCT04582292 - Laryngeal Manifestations of Connective Tissue Diseases
Recruiting NCT03214263 - Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases
Completed NCT04171362 - The Effect of Connective Tissue Massage in Patients With Migraine N/A
Completed NCT02392130 - A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin Phase 1
Completed NCT01656278 - An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis N/A
Recruiting NCT04915482 - TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2/Phase 3
Recruiting NCT05505409 - Efficacy and Safety of Pirfenidone in CTD-ILD Phase 4
Recruiting NCT02768259 - Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients N/A